Prab at 20:53, 26 April 2025

2025-04-26T20:53:32Z

← Older revision		Revision as of 20:53, 26 April 2025
Line 1:		Line 1:
	{{Short description\|A chemotherapy medication used in the treatment of prostate cancer}}		{{Short description\|A chemotherapy medication used in the treatment of prostate cancer}}
	~~{{Drugbox~~
	~~\| Verifiedfields = changed~~
	~~\| verifiedrevid = 477002679~~
	~~\| IUPAC_name = [(4R,5S,6S,8R,9S,10S,13S,14S,17S)-6,9,14-trihydroxy-10,13-dimethyl-3-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthren-17-yl] N-carbamoyloxycarbamate~~
	~~\| image = Estramustine.png~~
	~~\| width = 200~~
	}}

	'''Estramustine''' is a [[chemotherapy]] medication primarily used in the treatment of [[prostate cancer]]. It is a combination of [[estradiol]] and [[nitrogen mustard]], designed to target cancer cells by disrupting their growth and division. Estramustine is unique in its dual action as both a [[hormonal therapy]] and a [[cytotoxic agent]].		'''Estramustine''' is a [[chemotherapy]] medication primarily used in the treatment of [[prostate cancer]]. It is a combination of [[estradiol]] and [[nitrogen mustard]], designed to target cancer cells by disrupting their growth and division. Estramustine is unique in its dual action as both a [[hormonal therapy]] and a [[cytotoxic agent]].

Prab: CSV import

2025-03-22T19:10:25Z

CSV import

Show changes

Prab: CSV import

2025-02-20T01:03:04Z

CSV import

← Older revision		Revision as of 01:03, 20 February 2025
Line 101:		Line 101:
	{{Steroid-stub}}		{{Steroid-stub}}
	{{Antineoplastic-drug-stub}}		{{Antineoplastic-drug-stub}}
			== Estramustine ==
			<gallery>
			File:Estramustine.svg\|Estramustine
			File:Estramustine 3D ball.png\|Estramustine 3D Ball Model
			</gallery>

Prab: 1 revision imported

2025-01-13T20:08:31Z

1 revision imported

← Older revision		Revision as of 20:08, 13 January 2025
(No difference)

en>Boghog: consistent citation formatting

2024-07-01T04:53:04Z

consistent citation formatting

Show changes

Prab at 02:55, 27 September 2023

2023-09-27T02:55:44Z

New page

== Estramustine: A Comprehensive Overview of its Development and Clinical Significance ==

'''Estramustine''' (INN, USAN, BAN) is an intriguing compound that amalgamates the therapeutic traits of an [[estrogen]] with those of a cytostatic [[antineoplastic agent]]. Its journey, albeit not leading to a commercial launch, provides crucial learnings about the nuances of prodrugs, estrogens, and drug commercialization strategy.

=== Chemical and Pharmacological Properties ===

Chemically, estramustine falls under the category of [[estrogen ester]]. Specifically, it's the C3 normustine ester of [[estradiol]], a principal female sex hormone. This molecular architecture bestows it with the ability to act as a [[prodrug]] of estradiol when introduced into the human system.

A prodrug is ingeniously designed such that, post-administration, it undergoes metabolic conversion to yield a pharmacologically active entity. In the scenario of estramustine, enzymatic hydrolysis cleaves its ester bond, setting estradiol free to play its physiological and therapeutic role<ref>Cassidy J, Misset JL. (2002). Oxford textbook of palliative medicine. Oxford University Press.</ref>.

=== Estramustine Phosphate: A Therapeutic Derivative ===

Clinical parlance often revolves around '''estramustine phosphate''', a derivative of estramustine. Chemically, it's the C17β phosphate ester iteration of estramustine. Upon dosing, this compound metamorphoses into a prodrug for not just estramustine, but a cascade of related entities including:
* [[Estromustine]]
* [[Estradiol]]
* [[Estrone]]

Of these, while estradiol stands as a primary female sex hormone, estrone takes a backseat as a secondary one.

In the realm of therapeutic oncology, estramustine phosphate carved a niche for itself, especially in tackling [[prostate cancer]], a malignancy that's pervasive among males. This molecule's dual-faceted estrogenic and antineoplastic armory makes it adept at multi-pronged prostate cancer cell targeting<ref>Crawford ED, Eisenberger MA, McLeod DG, et al. (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med; 321:419-424.</ref>.

=== Market Dynamics and Clinical Decision-Making ===

Although estramustine never saw a market shelf, its phosphate offshoot did become a staple in prostate cancer therapeutics. Opting for one version of a drug over another is seldom arbitrary. Such determinations hinge on a spectrum of variables:
* Therapeutic prowess
* Augmented pharmacokinetics
* Fiscal feasibility in drug creation
* Intellectual property tactics
* The balance between efficacy and adverse effects

These choices offer a window into the interplay of scientific investigation, patient outcomes, and the commercial pulse of the drug industry<ref>Grabowski H. (2004). Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. Pharmacoeconomics. 22(Suppl 2):15-24.</ref>.

=== Conclusion ===

The narrative of estramustine and its phosphate derivative underlines the innovative spirit and strategic dexterity essential in drug R&D. Through a profound grasp of the chemistry and dynamics of compounds like these, the medical and scientific community can finetune therapeutic regimens for ailments such as prostate cancer, amplifying patient benefits.

== References ==
<references />
{{Estrogen receptor modulators}}
{{Androgen receptor modulators}}
[[Category:Abandoned drugs]]
[[Category:Antiandrogens]]
[[Category:Antigonadotropins]]
[[Category:Antineoplastic drugs]]
[[Category:Carbamates]]
[[Category:Chloroethyl compounds]]
[[Category:Diols]]
[[Category:Estradiol esters]]
[[Category:Estranes]]
[[Category:Estrogens]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Human drug metabolites]]
[[Category:Mitotic inhibitors]]
[[Category:Nitrogen mustards]]
[[Category:Organochlorides]]
{{Steroid-stub}}
{{Antineoplastic-drug-stub}}
{{nt}}

Estramustine - Revision history

Prab at 20:53, 26 April 2025

Prab: CSV import

Prab: CSV import

Prab: 1 revision imported

en>Boghog: consistent citation formatting

Prab at 02:55, 27 September 2023